FDA Should Have Larger Role In Trade Talks, Hamburg Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA commissioner believes the agency needs to have “a full place at the table,” rather than being summoned into the process late and viewed as obstructionist when it raises public health concerns.
You may also be interested in...
U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of U.S. FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says
Institute of Medicine report recommends how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad. It calls for FDA to provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.
GSK’s Blenrep: 15 Days From Confirmatory Trial Failure To Withdrawal Announcement
The first BCMA-targeting agent to gain approval in myeloma never became the blockbuster for which GSK had hoped, but Blenrep appears to have set a new standard for speed of voluntary withdrawal of an accelerated approval drug after a confirmatory trial failure.